See more : iRhythm Technologies, Inc. (IRTC) Income Statement Analysis – Financial Results
Complete financial analysis of Cardio Diagnostics Holdings, Inc. (CDIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cardio Diagnostics Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Skåne-möllan AB (publ) (SKMO.ST) Income Statement Analysis – Financial Results
- Paris Miki Holdings Inc. (7455.T) Income Statement Analysis – Financial Results
- Chico’s FAS, Inc. (CHS) Income Statement Analysis – Financial Results
- American Defense Systems, Inc. (ADFS) Income Statement Analysis – Financial Results
- Meyer Burger Technology AG (0QQ7.L) Income Statement Analysis – Financial Results
Cardio Diagnostics Holdings, Inc. (CDIO)
About Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 17.07K | 950.00 | 901.00 | 0.00 |
| Cost of Revenue | 0.00 | 16.00K | 0.00 | 0.00 |
| Gross Profit | 17.07K | -15.05K | 901.00 | 0.00 |
| Gross Profit Ratio | 100.00% | -1,584.21% | 100.00% | 0.00% |
| Research & Development | 145.18K | 40.45K | 31.47K | 1.50K |
| General & Administrative | 6.94M | 4.40M | 470.56K | 591.52K |
| Selling & Marketing | 158.51K | 92.70K | 103.32K | 5.48K |
| SG&A | 7.10M | 4.49M | 573.88K | 597.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 4.00K |
| Operating Expenses | 7.26M | 4.55M | 621.35K | 609.16K |
| Cost & Expenses | 7.26M | 4.55M | 621.35K | 609.16K |
| Interest Income | 1.07K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.74M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 111.62K | 16.00K | 16.00K | 10.67K |
| EBITDA | -1.53M | -4.64M | -604.45K | -598.50K |
| EBITDA Ratio | -8,966.90% | -465,254.42% | -67,086.35% | 0.00% |
| Operating Income | -7.24M | -4.55M | -620.45K | -609.16K |
| Operating Income Ratio | -42,440.43% | -478,784.32% | -68,862.15% | 0.00% |
| Total Other Income/Expenses | -1.13M | -112.53K | 0.00 | 4.00K |
| Income Before Tax | -8.38M | -4.66M | -620.45K | -605.16K |
| Income Before Tax Ratio | -49,087.81% | -490,630.00% | -68,862.15% | 0.00% |
| Income Tax Expense | 0.00 | 112.53K | 2.00 | 0.00 |
| Net Income | -8.38M | -4.66M | -620.45K | -605.16K |
| Net Income Ratio | -49,087.81% | -490,630.00% | -68,862.15% | 0.00% |
| EPS | -0.66 | -1.51 | -0.53 | -0.06 |
| EPS Diluted | -0.66 | -1.51 | -0.53 | -0.06 |
| Weighted Avg Shares Out | 12.69M | 3.09M | 1.16M | 9.51M |
| Weighted Avg Shares Out (Dil) | 12.69M | 3.09M | 1.16M | 9.51M |
Cardio Diagnostics Holdings, Inc. Regains Nasdaq Minimum Bid Price Requirement
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. today announced it has regained Nasdaq minimum bid price requirement.
CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Convenes Cardiovascular Care & Risk Roundtable at the 42nd Annual J.P. Morgan Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will be presenting a roundtable session on cardiovascular care and risk at the 42nd Annual J.P. Morgan Healthcare Conference.
Cardio Diagnostics Holdings, Inc's Convenes Cardiovascular Care & Risk Roundtable at the 42nd Annual J.P. Morgan Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will be presenting a roundtable session on cardiovascular care and risk at the 42nd Annual J.P. Morgan Healthcare Conference.
American Medical Association is Reviewing Cardio Diagnostics Holdings, Inc's Integrated Epigenetic-Genetic Cardiovascular Medicine Tests for CPT PLA Codes
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced the AMA CPT Editorial Panel is reviewing its Epi+Gen CHD and PrecisionCHD tests for CPT PLA codes.
Cardio Diagnostics shares rocket on validation of coronary heart disease detection test
Cardio Diagnostics Holdings shares added more than 75% on Monday after positive results from a trial of the company's coronary heart disease (CHD) test PrecisionCHD were published in the Journal of the American Heart Association. The company noted that PrecisionCHD...
Cardio Diagnostics Holdings, Inc. Announces Breakthrough in Coronary Heart Disease Detection with PrecisionCHD Test, Published in the Journal of the American Heart Association
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced the publication of its groundbreaking study in the Journal of the American Heart Association (JAHA),.
Family Medicine Specialists Selects Cardio Diagnostics' Epigenetic-Genetic Tests for Assessing Heart Attack Risk for its BlueCross BlueShield Patients
CHICAGO--(BUSINESS WIRE)--Family Medicine Specialists has selected Cardio Diagnostics' tests to identify patients at risk for coronary heart disease events.
Why Is Cardio Diagnostics (CDIO) Stock Up 45% Today?
Shares of cardiovascular medicine specialist Cardio Diagnostics (NASDAQ: CDIO ) are skyrocketing on Tuesday following the announcement of a key deal. Specifically, Vizient has awarded Cardio Diagnostics an “Innovation Technology” contract for its artificial intelligence (AI) driven molecular heart disease...
Cardio Diagnostics Holdings, Inc Receives Innovative Technology Contract from Vizient for Its Novel AI-Driven Precision Heart Disease Tests – Epi+Gen CHD & PrecisionCHD
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced its AI-driven molecular heart disease tests has received an Innovation Technology contract from Vizient, Inc.
Cardio Diagnostics Holdings, Inc and Aimil Ltd Join Forces to Introduce Cardiovascular Epigenetic Technologies to India
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced it has entered into a Supply and Distribution Agreement with Aimil Ltd.
Source: https://incomestatements.info
Category: Stock Reports